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Abstract 
Background: Reinforcement learning (RL) is a computational approach to understanding and 
automating goal-directed learning and decision-making. It is designed for problems which 
include a learning agent interacting with its environment to achieve a goal. For example, blood 
glucose (BG) control in diabetes mellitus (DM), where the learning agent and its environment are 
the controller and the body of the patient respectively. RL algorithms could be used to design a 
fully closed-loop controller, providing a truly personalized insulin dosage regimen based 
exclusively on the patient’s own data. 
Objective: In this review we aim to evaluate state-of-the-art RL approaches to designing BG 
control algorithms in DM patients, reporting successfully implemented RL algorithms in closed-
loop, insulin infusion, decision support and personalized feedback in the context of DM. 
Methods: An exhaustive literature search was performed using different online databases, 
analyzing the literature from 1990 to 2019. In a first stage, a set of selection criteria were 
established in order to select the most relevant papers according to the title, keywords and 
abstract. Research questions were established and answered in a second stage, using the 
information extracted from the articles selected during the preliminary selection. 
Results: The initial search using title, keywords, and abstracts resulted in a total of 404 articles. 
After removal of duplicates from the record, 347 articles remained. An independent analysis and 
screening of the records against our inclusion and exclusion criteria defined in Methods section 
resulted in removal of 296 articles, leaving 51 relevant articles. A full-text assessment was 
conducted on the remaining relevant articles, which resulted in 29 relevant articles that were 
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critically analyzed. The inter-rater agreement was measured using Cohen Kappa test, and 
disagreements were resolved through discussion. 
Conclusions: The advances in health technologies and mobile devices have facilitated the 
implementation of RL algorithms for optimal glycemic regulation in diabetes. However, there 
exists few articles in the literature focused on the application of these algorithms to the BG 
regulation problem. Moreover, such algorithms are designed for control tasks as BG adjustment 
and their use have increased recently in the diabetes research area, therefore we foresee RL 
algorithms will be used more frequently for BG control in the coming years. Furthermore, in the 
literature there is a lack of focus on aspects that influence BG level such as meal intakes and 
physical activity (PA), which should be included in the control problem. Finally, there exists a 
need to perform clinical validation of the algorithms. 
KEYWORDS: reinforcement learning; blood glucose control; artificial pancreas; closed-loop; 
insulin infusion 
Introduction   
Diabetes Mellitus (DM) is characterized by chronic high blood glucose (BG) level as a 
consequence of a metabolic disorder that occurs either when the pancreas does not produce 
enough insulin or when the body cannot effectively use the insulin it produces, leading to long–
term damage, dysfunction and failure of various organs [1]. According to the International 
Diabetes Federation approximately 1 in 11 adults has diabetes, which means 425 million adults 
worldwide suffered from these conditions in 2017. This represents 9.1% of the adult population, 
while trends suggest the rate would continue to rise. Furthermore, DM at least doubles a person's 
risk of early death, resulting in approximately 1.5 to 5.0 million deaths each year, while 12% of 
global health expenditure is spent on diabetes ($727 billion) [2]. Because of the high incidence and 
prevalence of diabetes, the share of research devoted to the disease is continuously increasing [3]. 
There exist three main types of diabetes: Type 1 Diabetes Mellitus (T1DM), in which the patient 
presents a deficient insulin production and requires daily administration of insulin, Type 2 
Diabetes Mellitus (T2DM), characterized by an ineffective use of insulin in the body, and 
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gestational diabetes, produced by a high BG levels during pregnancy. All of them require 
continuous management from patients and physicians in order to avoid complications [1]. 
Recent technological advances in medical wearable devices and sensor technologies, as well as 
the increase of processing power in mobile phones, have made an extensive acceleration of 
research activities possible in all aspects of diabetes. This new scenario has led to the application 
of machine learning (ML) and data mining techniques in the DM research field [4], with BG 
prediction appearing to be the most popular focus [5], indicating that artificial intelligence is 
increasingly common in DM solutions [6]. Among DM management tasks, the development of 
BG control strategies has been one of the most important issues during the last years [7]. For this 
reason, the design of control algorithms for DM is a very active research area approached from 
many different angles by a large number of scientists in different fields. Furthermore, there is a 
great need for more data-driven control strategies in this problem and the disadvantages of 
traditional algorithms suggest the use of data-driven ML algorithms [8]. Among these, 
reinforcement learning (RL) algorithms provide a highly promising approach that has been 
increasingly adopted in the area of control algorithms. Indeed, over the last few decades, RL has 
offered an appealing framework for the treatment and long-term management of chronic 
diseases. In this review, the goal is to analyze and assess existing RL algorithms for a closed-loop 
controller in DM. 
Diabetes and blood glucose control using reinforcement learning 
DM is often self-managed by the patient through multiple glucose level measurements 
throughout the day and administration of insulin via injection or a pump, which become a really 
challenging task for the patients, who have to deal with many complications during their daily 
life. Even with a due amount of vigilance, many patients may still suffer significant diabetes-









Figure 1: Self-managed blood glucose control. 
The artificial pancreas (AP) offers an efficacious and safe approach for treating DM [9], therefore 
it has become the holy grail of diabetes research [10]. The successful development of an AP 
consists of three primary components: a continuous glucose monitoring (CGM) system to 
continuously measure BG every five minutes or monitor glucose readings over a period of time, 
an insulin pump that can deliver precise amounts of insulin, and a control algorithm that 
translates data streaming from CGM into instructions for insulin pump. While the first two 
components have seen rapid technological gains in recent years, state-of-the-art controllers still 
require regular patient or caregiver intervention, operating in open-loop control with the user. 
Figure 2 shows a flowchart of the artificial pancreas BG control framework. This is a closed-loop 
model [11], where BG levels are measured by the CGM and, based on glucose concentrations, the 
controller determines the proper amount of insulin needed. This insulin dosage is applied by the 
insulin pump, affecting glucose system and changing BG level. Based on the changes produced 
in BG concentration, a new insulin dosage is calculated and applied. This process implies that 
only information measured from the patient is used to make decisions by the controller, without 






Figure 2: Blood glucose management based on artificial pancreas. 











This framework can be extended to a broader scope using mobile communication and wearables 
devices for health services, information, and data collection, obtaining a complete mHealth 
system [13]. The system would be able to monitor the patient physiological status while 
supervising the healthcare plan, allowing to include additional relevant information for diabetes 
care, such as food intake, physical activity (PA), infections and stress level. 
The principle of RL is based on the interaction between a decision-making agent and its 
environment [14]. In RL, the goal is to train an agent to take actions that result in preferable states. 
At each decision time point, the agent chooses an action for some given current state of the 
system. The environment reacts to this action and transitions to a new state. For the previous 
action taken, the agent now receives a positive or negative reinforcement from the environment. 
The mapping of state to action is called the policy. The goal of RL is to learn an optimal policy 
that maximizes the amount of rewards it receives over time. Figure 3 shows this RL framework, 
where the agent is the decision maker and learner while the environment is the thing the agent 




Figure 3: Reinforcement learning framework. 
Furthermore, in this framework there are additional sub-elements: the policy defining the 
behavior of the agent, the reward function defining the goal of the problem and the value function 
specifying the long-term desirability of states. Concretely, the value function indicates the total 
amount of reward expected by an agent when it starts from a given state and follows a given 
policy thereafter. Similarly, the action-value function indicates the total amount of reward 
expected by an agent when it starts from a given state, takes a given action and follows a given 
policy thereafter. Finally, some problems have the model of the environment, a sub-element 








Several approaches have been used in the literature in order to reach the RL goal: learn the 
optimal policy, which is the policy that is better than or equal to all other policies based on the 
values of the states. This have originated many RL methods such as temporal-difference learning, 
which learn by bootstrapping and perform updates from the current estimate of the value 
function, or actor-critic (AC) learning, which are algorithms formed by two different parts: an 
actor following a policy to select actions and a critic used to estimate the value function and 
criticizes the actions taken by the actor. Therefore these algorithms are characterized by a separate 
memory structure to explicitly represent the policy independent of the value function [14]. 
In the DM reinforcement learning task, the interstitial glucose curve is taken to be the state 
variable, as measured by the CGM. The action space consists of insulin dosage amounts. The 
agent is the controller. The environment is the patient’s glucose system. Finally, the reward 
function should measure the discrepancy between ideal and actual glucose levels.  
RL is particularly suited to situations where decisions are made sequentially along a timeline, 
actions depend on the observed state, effects manifest at later points in time than the actions that 
induced them (time delay), and there is some notion of preferred state(s). These features are 
certainly present in the DM controller challenge.  
Another advantage is that modeling the glucose-insulin dynamics can be entirely bypassed in RL. 
Furthermore, labeled training data is not required as in supervised learning strategies, but instead 
the agent can learn optimal policies without the necessity of first being trained on examples of 
“correct” actions to take.  
RL algorithms are uniquely suited to problems with inherent time delays. This presents a strong 
advantage in the diabetes application due to the time lags in both continuous glucose monitors 
(which actually measures subcutaneous glucose measurements) and insulin effect. RL naturally 
accommodates for these time delays because actions are allowed to have delayed effects and 
rewards are given for good behavior in the long run.  
Finally, this algorithm continuously adapts and evolves with the user, which leads to a truly 
personalized analysis. In contrast, traditional statistics and ML often operate by borrowing 
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strength across subjects. Additional convincing arguments for the use of RL in the DM scenario 
are given in [8]. 
Methods 
The purpose of the review is to identify, assess and analyze the state-of-the-art RL algorithms and 
strategies focusing on its applications towards BG control in people with diabetes. As a result, a 
comprehensive literature search was conducted from 5th June 2019 to 3rd August 2019. The search 
was performed using different online databases such as ACM digital library, DBLP Computer 
Science Bibliography, Google Scholar, IEEE Xplore, Journal of American Medical Informatics 
Association (JAMIA), PubMed and ScienceDirect. Relevant papers were further extracted from 
the reference lists of the selected articles. The search process covers a specified timeframe from 
1990 to 2018 and considered peer reviewed journal articles and conference proceedings. The 
search was conducted using different combination of strings along with “reinforcement learning” 
including “artificial pancreas”, “blood glucose control”, “closed-loop in diabetes”, “decision 
making in diabetes”, “decision support in diabetes”, “insulin infusion”, “insulin pump” and 
“personalized feedback in diabetes”. For the purpose of effective searching strategy, the search 
strings were combined using Boolean function such as “And” and “Or”. During the search, 
relevant articles were identified by reviewing the title, keywords, and abstracts for a preliminary 
filter based on the inclusion and exclusion criteria. A full-text assessment was done on only 
articles that seemed relevant according to our inclusion and exclusion criteria. Information 
extraction were also done based on some structured predefined categories that is in line with our 
inclusion and exclusion criteria, which were defined based on discussions and brainstorming 
among the authors.    
Inclusion and exclusion criteria  
To be considered in this review, the study should develop and test RL algorithms and strategies 
based on people with diabetes and in addition fulfil the following conditions: focus on BG control 
and be published between 1990 and 2019. 
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As a result, studies outside of the stated scope were excluded from the review including all 
studies presented in other languages than English. 
Data categorization and Data collection 
Extraction of information from the selected studies was conducted using some predefined and 
structured categories, which were defined based on discussions and brainstorming among the 
authors. The categories were defined to fully assess and evaluate the state-of-the-art of RL 
algorithms and strategies developed and tested on BG control for people with diabetes. 
Subjects: This category defines the nature and characteristics of the subject used in algorithm 
development and testing, which includes age, gender, type of DM and nature of the subjects; in 
silico and real subjects.  
Data sources: This category defines different kind of data sources the studies have used to develop 
and test the RL algorithms, which include data sources like CGM devices, insulin pumps, 
different BG dynamics simulators and others. 
Preprocessing: This category defines the kind of preprocessing performed on the raw data and the 
various approaches employed in the processes, including glycemic ranges, sparsification 
(detecting novel information) and others.  
RL Approach: This category defines the reinforcement algorithm approach used to develop the 
control algorithm, including tabular solution methods and approximate solution methods. 
Class of RL: This category defines the class of RL algorithms used to develop and test the control 
algorithm, which includes AC learning, Q-learning, Sarsa and others. 
Exploitation versus exploration: This category encompasses the exploitation-exploration dilemma 
in RL algorithms, which involves making the best decision given the current information or 
gathering more information with sacrifices for a long-term benefit.  In this regard, it pinpoints the 
approached favored by the studies to solve the dilemma. 
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State space: This category encompasses the definition of the state space, its nature and defining 
parameters used in the control algorithms, that is the actual situation of the environment in which 
the agent finds itself. The nature of the state space is either continuous or discrete. The defining 
parameters include key diabetes parameters such as BG, insulin, diet, PA and others.   
Action space: This category encompasses the definition of the action space, its nature and defining 
parameters, which is a set of all possible actions the agent is entitled to choose. The nature of the 
action space is either continuous or discrete. The defining parameters include different actions 
such as insulin dose, food intake, PA and others.  
Planning: This category encompasses the planning techniques used in the reinforcement 
algorithms. It includes either a model-based or model-free approach. 
Generalization Approaches: This category determines the approaches to address the problem of 
learning in large spaces. Among these techniques we can find policy gradient method, Gaussian 
process (GP) regression and others. 
Performance metrics or evaluation criteria: This category defines performance metrics the studies 
have used to evaluate the developed BG control algorithms. It includes different approaches such 
as predefined target ranges, control variability grid analysis (CVGA), comparison with reference 
value and others. 
Model of optimal behavior: This category considers the different models of optimality, where there 
are three main models in this area: the finite-horizon model, the infinite-horizon discounted 
(IHD) model and the average-reward (AR) model. 
Reward function: This category defines the kind of reward function used to develop the control 
algorithms, which measures the success or failure of an agent according to a set of chosen actions. 
A reward is defined based on the objective of the task at hand and the expert knowledge. As a 
result, various kinds of reward functions have been defined in the literature and this category 
pinpoint widely adopted reward functions.   
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Literature evaluation  
Papers were evaluated based on the above predefined categories to evaluate the state-of-the-art 
approaches and strategies used in RL algorithms for BG control in people with diabetes. The first 
evaluation and analysis was done based on data characteristics including data sources, subjects 
and preprocessing approach. The second evaluation and analysis were conducted based on RL 
strategies including class of RL algorithms and its approaches. The third analysis was carried out 
based on exploitation versus exploration, to reveal the state-of-the-art approaches in solving the 
dilemma involved. The fourth evaluation and analysis was conducted based on state and action 
space including their respective nature and defining parameters. The fifth evaluation and analysis 
was carried out based on planning approaches employed during development. The sixth 
evaluation and analysis was conducted based on reward function used to learn the agent. Note 
that the number of features extracted might exceed the number of reviewed articles since many 
features are reported in the literature. Therefore, the number of findings in each category might 
vary from the number of total studies included in the review, since more than one approach can 
be considered in the same article. 
Results 
Relevant literatures  
RL is a quickly growing field, and its application to diabetes BG control is growing even more 
rapidly, as found in the literature publication dates, with only 2 publications before 2012 while 
27 publications between 2012 and 2019. From those articles, 8 were published in just the last year.  
The initial search using title, keywords, and abstracts resulted in a total of 404 articles. After 
removal of duplicates from the record, 347 articles remained for further analysis. An independent 
analysis and screening of the records against our inclusion and exclusion criteria resulted in 
removal of 296 articles, leaving 51 relevant articles. A full-text assessment was conducted on the 
remaining relevant articles, which resulted in 29 relevant articles that were critically analyzed as 
shown in Figure 4 below. The inter-rater agreement was measured using Cohen Kappa test [15], 
























Figure 4: Flow diagram of the process. 
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Evaluation of literature  
The reviewed articles are evaluated, as described earlier, based on the above predefined 
categories. The results obtained are showed below in Table 1. 
Table 1: Features extracted from the papers. 
Ref. Subjects Type 
of DM 
Data source Preprocessing Class of RL Exploitation 
vs. 
exploration 
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models [25, 40]. 





























































































































Data characteristics  
Subjects  
The reviewed articles are mainly based on real and in silico (simulated) subjects for T1DM and/or 
T2DM, as shown in Table 1 above. Almost all studies developed and tested algorithms for T1DM 
(82.75%, 24/29), while only 2 studies (6.9%) are based on T2DM, 2 other studies (6.9%) consider 
both types of diabetes, and 1 study (3.45%) does not specify the type of diabetes. Moreover, most 
of the studies (76.67%, 23/30) have relied on in silico subjects and only 20% of the studies (6/30) 
have tried to test the algorithm on real subject data sets, while the remaining group (3.33%, 1/30) 
relies on mixed data sets such as using simulated BG and insulin along with real meal data sets. 
Data sources 
The reviewed articles have used various kinds of data sources for the development of the control 
algorithm using RL, as shown in Table 2 below. Accordingly, the most used data source is the 
UVA/PADOVA simulator [20] (35.48%, 11/31) followed by the Bergman’s minimal model [25] 
(12.90%, 4/31), AIDA model [17] (12.90%, 4/31) and public available real datasets (12.90%, 4/31). 
The third most used are the Hovorka model [40] (6.45%, 2/31) and combination of the minimal 
model with part of the Hovorka model, one of them using actual meal data (6.45%, 2/31). The 
fourth most used data sources includes, private datasets (3.23%, 1/31), Palumbo model [28] 
(3.23%, 1/31), real datasets from a clinical study (3.23%, 1/31) and simulated data generated by 
researchers (3.23%, 1/31). The real datasets are mainly from CGM (3.23%, 1/31), insulin pump 
(9.68%, 3/31), accelerometer (3.23%, 1/31), automatic electronic recording device (3.23%, 1/31), 
paper records (3.23%, 1/31), multiple daily injections (3.23%, 1/31), and actual meal data records 
(3.23%, 1/31). 
Table 2: Data sources used by the studies. 
Data sources Count Percentages 
UVA/PADOVA simulator 11 35.48% 
Bergman’s minimal model 4 12.90% 
AIDA model 4 12.90% 
Public available data set (Real data) 4 12.90% 
Hovorka model 2 6.45% 
Combination models 2 6.45% 
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Palumbo model 1 3.23% 
Private data set (Real data) 1 3.23% 
Clinical study (Real data) 1 3.23% 
Simulated data generated by themselves 1 3.23% 
 
Preprocessing 
Preprocessing is a crucial component in RL strategies. In this regard, extracting a range of 
glycemic features ranked as most used (40.63%, 13/32) followed by the absence of a preprocessing 
stage (34.38%, 11/32), as shown in the Table 3 below. Bayesian active learning (BAL) (9.37%, 3/32) 
and sparsification (9.37%, 3/32) are the third most used techniques followed by Bayesian surprise 
(6.25%, 2/32). 
Table 3: Preprocessing techniques used in the reviewed literature. 
Preprocessing Count Percentages 
Extracting a range of glycemic features 13 40.63% 
No preprocessing 11 34.38% 
BAL 3 9.37% 
Sparsification 3 9.37% 
Bayesian surprise 2 6.25% 
 
Reinforcement learning strategies  
Class of reinforcement learning algorithms  
There are various classes of RL algorithms such as AC learning, Q-learning, Sarsa to mention a 
few. In this regard, the most popular RL algorithms is found to be the AC learning (36.67%, 11/30) 
followed by Q-learning (10%, 3/30) and Gaussian processes reinforcement learning (GPRL) (10%, 
3/30), as shown in the Table 4 below. Sarsa (6.68%, 2/30) and dynamic programming (DP) (6.68%, 
2/30) are ranked as the third most popular reinforcement learning algorithms followed by 
Gaussian process dynamic programming (GPDP) (3.33%, 1/30), learning automaton (3.33%, 1/30), 
V-learning (3.33%, 1/30), model-free approximate/adaptive dynamic programming (ADP) 
algorithm (3.33%, 1/30), reinforcement-learning optimal control algorithm (RLOC) (3.33%, 1/30), 
linearly-solvable Markov decision process (LSMDP) (3.33%, 1/30), fitted Q-iteration (3.33%, 1/30), 
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reinforcement learning with feedforward (RLFF) (3.33%, 1/30), and deep Q-network (DQN) 
(3.33%, 1/30). 
Table 4: Class of reinforcement learning algorithms. 
Class of reinforcement learning algorithms Count Percentages 
AC learning 11 36.67% 
Q-learning 3 10% 
GPRL 3 10% 
Sarsa 2 6.68% 
DP 2 6.68% 
GPDP 1 3.33% 
Learning automaton 1 3.33% 
V-learning 1 3.33% 
ADP 1 3.33% 
RLOC 1 3.33% 
LSMDP 1 3.33% 
Fitted Q-iteration 1 3.33% 
RLFF 1 3.33% 
DQN 1 3.33% 
 
Reinforcement learning approaches 
The approaches in RL in the reviewed literature could be roughly categorized as tabular solution 
methods and approximate solution methods. In this regard, as shown in Table 5 below, 
approximate solution methods (73.33%) are more popular than the tabular solution methods 
(26.67%). 
Table 5: Approaches to reinforcement learning for blood glucose control in diabetes patient. 
RL solution Count Percentages 
Approximate Solution Methods 22 73.33% 
Tabular Solution Methods 8 26.67% 
 
Exploitation-exploration dilemma  
In RL algorithm applications, exploitation-exploration dilemma is one of the most important 
constituents of the design choices. In this regard, Gaussian distribution function (24.25%, 8/33) is 
the most popular choice, as shown in Table 6 below. BAL (12.12%, 4/33) and ε-greedy policy 
(12.12%, 4/33) are the second most important choices followed by greedy policy (9.09%, 3/33) and 
17 
 
exploration noise (9.09%, 3/33). Least squares algorithm (6.06%, 2/33) and uniform distribution 
(UN) (6.06%, 2/33), are the fourth most popular choices followed by truncated gaussian (TG) 
(3.03%, 1/33) and randomized decision rule (3.03%, 1/33). However, surprisingly (15.15%, 5/33) of 
the studies either did not report their choices or did not consider it at all. 
Table 6: Various design choices towards exploitation-exploration dilemma. 
Exploitation-exploration dilemma Count Percentages 
Gaussian distribution 8 24.25% 
BAL 4 12.12% 
ε-greedy 4 12.12% 
Greedy policy 3 9.09% 
Exploration noise 3 9.09% 
Least squares algorithm 2 6.06% 
UN 2 6.06% 
TG 1 3.03% 
Randomized decision rule 1 3.03% 
Unspecified 5 15.15% 
  
State and Action Space 
The other most important constituents design choices of RL applications is defining the nature 
and parameters of the agent state and action spaces. In this section, we will present the nature of 
the state and action spaces along with their defining parameters.  
State Space  
Nature of the state space 
Based on the reviewed studies, the nature of the state space could be grouped in two; continuous 
and discrete state space. In this regard, most of the studies have relied on continuous state space 
(73.33%), as shown in Table 7 below. 
Table 7: Nature of the state space.  
State space nature Count  Percentage  
Continuous  22 73.33% 





State Space Defining Parameters 
Various key diabetes parameters have been used to define the state spaces, as shown in Table 8 
below. Based on the reviewed studies, the most popular parameter is BG level (43.34%, 13/30) 
followed by BG level and insulin dose (30%, 9/30). BG level and carbohydrate (CHO) intake 
(6.67%, 2/30), and BG level and the interstitial insulin activity (6.67%, 2/30) are the third most used 
parameters. The fourth most used parameters include the following combinations: 
• BG level, glucose absorption rate, measurement times during the day, CHO intake and 
PA (3.33%, 1/30). 
• BG level, weight and PA (3.33%, 1/30). 
• BG level, PA and CHO intake (3.33%, 1/30). 
• Patient level variables, BG related variables, periodic vital signs and laboratory values 
(3.33%, 1/30). 
Table 8: State space defining parameters. 
State space defining parameters Count Percentages 
BG level 13 43.34% 
BG level and insulin dose 9 30% 
BG level and CHO intake 2 6.67% 
BG level and interstitial insulin 
activity 
2 6.67% 
BG level, glucose absorption 
rate, measurement times during 
the day, CHO intake and PA 
1 3.33% 
BG level, weight and PA 1 3.33% 
BG level, PA and CHO intake 1 3.33% 
Patient level variables, BG 
related variables, periodic vital 




Nature of the Action space 
As for the state spaces, the nature of the action space is inline and could be grouped into 
continuous or discrete as shown in Table 9 below. Accordingly, most of the studies have relied 
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on continuous action spaces (66.67%, 20/30), while only 33.33% of the studies have relied on a 
discrete space. 
Table 9: Nature of the action spaces. 
Action Space Nature Count  Percentage  
Continuous 20 66.67% 
Discrete 10 33.33% 
 
Action Space Defining Parameters   
Various action parameters taken by the diabetes patients to manage his/her BG are considered in 
the reviewed studies, as show in Table 10 below. In this regard, insulin dose is the most popular 
action parameter used in the studies followed by insulin dose, PA and food intake (3.23%, 1/31) 
and targeted BG level (3.23%, 1/31). 
Table 10: Action space defining parameters. 
Action Space Parameters Count  Percentage 
Insulin dose 29 93.54% 
Insulin dose, PA and food intake 1 3.23% 
Targeted BG level 1 3.23% 
 
Planning  
Planning is another important constituent of the design choices in the RL applications. 
Accordingly, based on the studied articles planning approaches could be roughly categorized as 
model-based or model-free approaches. In this regard, a model-free approach (79.31%, 23/29) is 
the most widely exploited approach in diabetes BG control algorithms, as shown in the Table 11 
below. 
Table 11: Planning approaches. 
Planning  Count  Percentage  
Model-free 23 79.31% 




Generalization Approaches  
Generalization is a straight forward approach for high dimensional and continuous state and 
action spaces in real world control tasks, where a discrete representation is intractable. In this 
regard, the reviewed literatures have exploited various generalization approaches as shown in 
Table 12 below. The most used generalization approach is policy gradient method (11/24, 45.83%) 
followed by nonparametric regression (7/24, 29.16%). Function approximation (3/24, 12.5%) is the 
third most used generalization approach. The fourth most used generalization approaches 
include continuous action-set learning automata (CALA) (1/24, 4.17%), tile-coding (1/24, 4.17%), 
and mix from policy gradient and function approximation (1/24, 4.17%). 
Table 12: Generalization Approaches.  
Generalization issues Count  Percentages 
Policy Gradient Method 11 45.83% 
Nonparametric regression 7 29.16% 
Function approximation 3 12.5% 
CALA 1 4.17% 
Tile-coding 1 4.17% 
Mix from Policy gradient and function approximation 1 4.17% 
 
Performance Metrics or Evaluation Criteria 
Various kinds of evaluation criteria have been used to measure the performance of the algorithm 
towards the specified goal as shown in Table 13 below. In this regard, the most used approach is 
predefined target ranges (14/36, 38.90%) followed by comparison with reference value (5/36, 
13.89%) and CVGA (4/36, 11.11%). Low blood glucose index (LBGI) (3/36, 8.33%) is the fourth 
most used approaches followed by on-line behavior monitoring (2/36, 5.55%), high blood glucose 
index (HBGI) (2/36, 5.55%), and total daily insulin (TDI) (2/36, 5.55%). The sixth most used 
performance metrics are risk function (1/36, 2.78%), mean amplitude of glucose excursion 
(MAGE) (1/36, 2.78%), optimal insulin treatment policy (1/36, 2.78%) and ability to reject the effect 
of meal disturbance and to overcome the variability in the glucose-insulin dynamics from patient 




Table 13: Performance metrics or evaluation approaches. 
Performance metrics or evaluation criteria Count  Percentages 
Predefined target ranges 14 38.90% 
Comparison with reference value 5 13.89% 
CVGA 4 11.11% 
LBGI 3 8.33% 
HBGI 2 5.55% 
TDI 2 5.55% 
On-line behavior monitoring 2 5.55% 
Risk function 1 2.78% 
MAGE 1 2.78% 
Meal disturbance rejection and overcoming variability 1 2.78% 
Optimal insulin treatment policy 1 2.78% 
 
Model of optimal behavior 
Another important constituent of reinforcement algorithm design choices includes the 
description of model of optimal behavior, as shown in Table 14 below. In this aspect, the reviewed 
papers mainly exploited the IHD model (25/29, 86.20%) and only (1/29, 3.45%) used the AR model. 
Surprisingly, (3/29, 10.35%) have not stated anything related to the optimal behavior model. 
Table 14: Model of optimal behavior.  
Model of optimal behavior Count  Percentages 
IHD model 25 86.20% 
AR model 1 3.45% 
Unspecified  3 10.35% 
 
Reward Function 
The reward function is also among the crucial constituents of design choices for a successful RL 
design. In this regard, choosing the reward function relies on the expert designing and 
developing the algorithms. As a result, the expert is free to choose the reward function based on 
the specific task and objective he/she is in need of achieving. With the same token, the reviewed 
studies have reported various types of reward functions based on their nature and defining 




Table 15: Reward functions. 
Reference Reward/Cost function Comments 
[16] 
𝑟𝑟�𝐺𝐺(𝑡𝑡)� = −1 + 𝑒𝑒−
(𝐺𝐺(𝑡𝑡)−𝐺𝐺𝑋𝑋)2
2𝑎𝑎2 ;   𝑟𝑟 ∈ [−1, 0] Gaussian reward function where: 
𝐺𝐺(𝑡𝑡) - Instantaneous reading from the glucose sensor 
𝐺𝐺𝑋𝑋 - Reference value of the glucose concentration 






𝐺𝐺𝐴𝐴(𝑘𝑘) - Actual BG level 
?̅?𝐺𝑁𝑁 - BG average normal value 
[19] 𝑐𝑐(𝑥𝑥𝑘𝑘) = 𝑎𝑎ℎ𝐹𝐹1𝑘𝑘 + 𝑎𝑎𝑙𝑙𝐹𝐹2𝑘𝑘 𝐹𝐹1𝑘𝑘 and 𝐹𝐹2𝑘𝑘 - Features describing the glycemic profile 
𝑎𝑎ℎ and 𝑎𝑎𝑙𝑙 - weights for scaling the hypo and hyperglycemia 
components 
[21] N/A N/A 
[22] Reward +1 if next BGL measurement is within a 
predefined range 




𝑟𝑟�𝐺𝐺(𝑡𝑡)� = −1 + 𝑒𝑒−
(𝐺𝐺(𝑡𝑡)−𝐺𝐺𝑋𝑋)2
2𝑎𝑎2 ;   𝑟𝑟 ∈ [−1, 0] Gaussian reward function where: 
𝐺𝐺(𝑡𝑡) - Instantaneous reading from the glucose sensor 
𝐺𝐺𝑋𝑋 - Reference value of the glucose concentration 
𝑎𝑎 - Width of the desired glucose band for normoglycemia 
[24] 𝑟𝑟𝑡𝑡(𝑥𝑥,𝑎𝑎) = −|(𝐺𝐺 − 80)| The reward is set equal to the difference of the glucose 
concentration from its target value of 80 mg/dl. This value 
has been considered as a reference set point in 
normoglycemic range of BG. 
[26] N/A Function of the difference of the A1C from its target value 7. 
[27] 𝑟𝑟𝑡𝑡(𝑠𝑠, 𝑎𝑎) = −�𝐺𝐺(𝑡𝑡) − 𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟(𝑡𝑡)� The reward is set equal to the difference of the plasma 
glycaemia signal from a reference signal. 
[29] 
𝑅𝑅(𝑡𝑡) = �
𝑎𝑎ℎ ∙ 𝐸𝐸(𝑡𝑡)    𝑖𝑖𝑖𝑖 𝐺𝐺(𝑡𝑡) ≥ 𝐺𝐺𝐻𝐻
𝑎𝑎𝑙𝑙 ∙ 𝐸𝐸(𝑡𝑡)     𝑖𝑖𝑖𝑖 𝐺𝐺(𝑡𝑡) < 𝐺𝐺𝐿𝐿





𝐸𝐸(𝑡𝑡) = �𝐺𝐺(𝑡𝑡) − 𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟� 
𝑎𝑎ℎ - Hyperglycemia penalty 
𝑎𝑎𝑙𝑙 - Hypoglycemia penalty 
𝐺𝐺𝐻𝐻 - Hyperglycemia bound 
𝐺𝐺𝐿𝐿 - Hypoglycemia bound 
𝐸𝐸(∙) - Current error between the measured and the desired 
glucose concentration value 
𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟 - reference glucose concentration value 
[30] N/A The state is used by the algorithm for the estimation of the 
long-term expected costs 
[31] 𝑙𝑙𝑝𝑝(𝐱𝐱,𝑢𝑢𝑝𝑝) = 𝑞𝑞(𝐱𝐱) + 𝐾𝐾𝐾𝐾(𝑝𝑝(𝐱𝐱�|𝐱𝐱,𝑢𝑢𝑝𝑝)||ℎ(𝐱𝐱�|𝐱𝐱)) 𝑞𝑞(𝐱𝐱) - State cost 
𝐾𝐾𝐾𝐾(• ‖ •) - Kullback–Leibler distance 
𝑝𝑝(𝐱𝐱�|𝐱𝐱,𝑢𝑢𝑝𝑝) - Optimal actions under uncertainty 
ℎ(𝐱𝐱�|𝐱𝐱) - Passive system dynamics 
𝐱𝐱 - Actual state 
𝐱𝐱� - Next state 
𝑢𝑢𝑝𝑝 - Control action 
[32] 𝑙𝑙(𝐱𝐱,𝑢𝑢) = ℎ𝑞𝑞(𝐱𝐱) + 𝐾𝐾𝐾𝐾(𝑝𝑝𝑢𝑢(𝐱𝐱𝑘𝑘+1|𝐱𝐱𝑘𝑘)||𝑝𝑝0(𝐱𝐱𝑘𝑘+1|𝐱𝐱𝑘𝑘)) 𝑞𝑞(𝐱𝐱) - State cost 
𝐾𝐾𝐾𝐾(• ‖ •) - Kullback–Leibler distance 
𝑝𝑝𝑢𝑢(𝐱𝐱𝑘𝑘+1|𝐱𝐱𝑘𝑘) - Controlled diffusion process 
𝑝𝑝0(𝐱𝐱𝑘𝑘+1|𝐱𝐱𝑘𝑘) - Passive dynamics 
𝐱𝐱𝑘𝑘 - State at time k 
𝐱𝐱𝑘𝑘+1 - State at time k + 1 
𝑢𝑢 - Control action 
[33] 
𝑔𝑔(𝐺𝐺𝑡𝑡) = −1 + 𝑒𝑒
−(𝐺𝐺𝑡𝑡−?̅?𝐺)
2
2𝑎𝑎2 ;   𝑔𝑔 ∈ [−1, 0] Gaussian reward function where: 
𝐺𝐺𝑡𝑡 - Instantaneous reading from the glucose sensor 
?̅?𝐺 - Reference value of the glucose concentration 
𝑎𝑎 - Width of the desired glucose band for normoglycemia 
[34] 𝑐𝑐(𝑥𝑥𝑘𝑘) = 𝑎𝑎ℎ𝑥𝑥𝑘𝑘1 + 𝑎𝑎𝑙𝑙𝑥𝑥𝑘𝑘2 𝑥𝑥𝑘𝑘1 and 𝑥𝑥𝑘𝑘2 - Features describing the glycemic profile 




[35] 𝑟𝑟(𝑔𝑔) = 𝑟𝑟𝑙𝑙(𝑔𝑔) − 𝑟𝑟𝑛𝑛(𝑔𝑔) 
 









Heuristically defined. Positive rewards are obtained for the 
healthiest states and negative rewards are obtained at 
undesired BG levels. 
𝑔𝑔𝑙𝑙 - BGL-state 
𝑔𝑔𝑙𝑙ℎ - Most healthy BGL 
𝐈𝐈 - Standard indicator function 













They define a score function that matched their objectives. 
This function penalizes when glucose level is out of the 
ideal range (4-8 mmol/L). 
[37] Weighted sum of glycaemic events (hypo- and 
hyperglycaemic episodes) over the 60 minutes preceding 
and following time 𝑡𝑡. 
Weights are: 
−3 when glucose ≤ 70 (hypoglycemic) 
−2 when glucose > 150 (hyperglycemic) 
−1 when 70 < glucose ≤ 80 or 120 < glucose ≤ 150 (borderline 
hypo- and hyperglycemic) 
0 when 80 < glucose ≤ 120 (normal glycaemia) 
[38] 
𝐽𝐽 = � (𝛼𝛼𝐺𝐺∆2 + 𝛽𝛽𝑢𝑢∆2)
∞
0
𝑑𝑑𝑑𝑑 𝐺𝐺 - BG concentration 
𝑢𝑢 - Infusion rate of the insulin pump 
𝛼𝛼 > 0 and 𝛽𝛽 > 0 - Weighting constants 
[39] 𝑐𝑐(𝒙𝒙𝑡𝑡) = 𝑎𝑎ℎ𝑥𝑥𝑡𝑡1 + 𝑎𝑎𝑙𝑙𝑥𝑥𝑡𝑡2 𝑥𝑥𝑡𝑡1 and 𝑥𝑥𝑡𝑡2 - Features describing the glycemic profile 
𝑎𝑎ℎ and 𝑎𝑎𝑙𝑙 - weights for scaling the hypo and hyperglycemia 
components 
[41] 90-day mortality status:  
+100 for patients who survived 90 days after their 
admission 
-100 for those who were deceased before 90 days after 
their admission 
N/A 
[42] 𝑟𝑟𝑘𝑘 = 𝐱𝐱𝑘𝑘𝑇𝑇𝐐𝐐𝐱𝐱𝑘𝑘 + 𝑢𝑢𝑘𝑘𝑇𝑇𝑅𝑅𝑢𝑢𝑘𝑘 𝐱𝐱 - State of the model formed by BG level and interstitial 
insulin activity 
𝑢𝑢 - Insulin dose 
𝐐𝐐 and 𝑅𝑅 - Weighting factors 
[43] 𝑟𝑟𝑖𝑖′ = |𝑔𝑔𝑖𝑖+1 − 90| 𝑔𝑔𝑖𝑖  - Plasma glucose value 
90 mg/dL = 5mmol/L is taken as the optimal blood glucose 
level 
[44] 𝑟𝑟𝑘𝑘+1 = 𝐱𝐱𝑘𝑘𝑇𝑇𝐐𝐐𝐱𝐱𝑘𝑘 + 𝑢𝑢𝑘𝑘𝑇𝑇𝑅𝑅𝑢𝑢𝑘𝑘 𝐱𝐱 - State of the model formed by BG level and interstitial 
insulin activity 
𝑢𝑢 - Insulin dose 
𝐐𝐐 and 𝑅𝑅 - Weighting factors 
[45] 𝑅𝑅 = 𝑟𝑟𝑖𝑖𝑠𝑠𝑘𝑘(b𝑡𝑡+1) − 𝑟𝑟𝑖𝑖𝑠𝑠𝑘𝑘(b𝑡𝑡) Where 𝑟𝑟𝑖𝑖𝑠𝑠𝑘𝑘 is the asymmetric blood glucose risk function 
defined as: 
𝑟𝑟𝑖𝑖𝑠𝑠𝑘𝑘(𝑏𝑏) = 10 ∗ (1.509 ∗ log(𝑏𝑏)1.084 − 5.381) 
b𝑡𝑡 - Blood glucose value 
[47] 𝑐𝑐𝑘𝑘 = 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 + 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑦𝑦𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 and 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 - Features describing the glycemic 
profile 
𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 and 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑦𝑦 - weights for scaling the hypo and 
hyperglycemia components 
[48] 𝑐𝑐𝑘𝑘 = 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 + 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑦𝑦𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 and 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 - Features describing the glycemic 
profile 
𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 and 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑦𝑦 - weights for scaling the hypo and 
hyperglycemia components 
[49] 𝑐𝑐𝑘𝑘 = 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 + 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑦𝑦𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 and 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 - Features describing the glycemic 
profile 




[50] 𝑐𝑐𝑘𝑘 = 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 + 𝑎𝑎ℎ𝑦𝑦𝑝𝑝𝑦𝑦𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑟𝑟𝑟𝑟 and 𝐹𝐹𝑘𝑘_ℎ𝑦𝑦𝑝𝑝𝑦𝑦 - Features describing the glycemic 
profile 




Over the last decade, there has been an increase in the use of ML techniques for diabetes 
management, which has meant important advances in this research area. Concretely, RL 
algorithms have arisen as a competitive solution for BG control in diabetes patients during recent 
years, especially in T1DM where its use is more extended. These algorithms were applied on in-
silico subjects in most cases. Clinical data is usually hard to obtain because the patients have to 
collect carefully their data and in addition, there are ethical issues related to the use of such data. 
However, although the current situation could be marked by the difficulties of obtaining real data 
from diabetic patients, there exists a need to move the studies from simulated data to clinical data 
in order to facilitate the validation of the algorithms. Regarding the source of these data, most of 
the studies relies on the in-silico patient cohort provided by UVA/PADOVA simulator [20] to 
evaluate the algorithms. The main reason for this is presumably that it is the only in-silico diabetes 
model accepted by the FDA as a substitute for pre-clinical animal testing of new treatment 
strategies for T1DM, which is the prelude to the clinical studies on humans. This simulator is 
followed by AIDA and Bergman’s minimal models [17, 25], which are the second most common 
option, probably because these are simple models and for this reason it is easier to work with 
them. For example, Bergman’s minimal model does not present any delay in insulin action, which 
fits better with the RL framework.  Once again, the lack of real data sets is evident and so is the 
validation of the problem since we only found one clinical study in the literature [18]. After 
obtaining the data, preprocessing is performed to extract a range of glycemic features, which in 
some of the studies is used to establish different glycemic ranges in order to discretize the state 
space [22, 24, 26]. However, studies using raw BG levels also occurs frequently. Other techniques 
such as BAL, which samples only relevant data, and sparsification, which determines whether 
arriving data provide valuable information are interesting options in future research [16]. 
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Moving the discussion to the RL framework, we can find two different solutions: tabular methods 
and approximate methods, the latter being most used for this BG control problem. Tabular 
methods are used to face problems with small state and action spaces, while approximate 
methods are well-suited to problems with large state and action spaces. Since current BG control 
research is focused on developing the AP, which includes the use of a CGM and insulin pump 
that generate continuous blood glucose measurements and continuous insulin infusion, we found 
that we are facing continuous spaces and therefore approximate solutions fit well given the nature 
of the problem. Moreover, in scenarios with continuous or large discrete state and action spaces 
we need to use generalization techniques to learn information and transfer knowledge between 
similar states and actions, since in a large and smooth state space we generally expect similar 
states to have similar values and similar optimal actions [51]. In this regard, we found in the 
literature that the most used generalization technique is policy gradient method, characterized 
by learning a parametrized policy that does not use the value function to select actions [14]. 
Another much used generalization technique is GP regression, which is an interpolation method 
with the interpolated values modeled by a GP governed by prior covariances. Further 
information about GP in ML can be found in [52]. 
Among the RL algorithms analyzed during this review, AC methods are most used. These 
algorithms produce an approximate solution based on policy gradient methods that learn a 
parametrized policy instead of learning which action is better in each state. Therefore, action-
value functions are not directly used by these methods to select actions [14]. Regarding tabular 
methods Q-learning is the most used approach, which is an off-policy temporal-difference control 
algorithm in which the learned action-value function directly approximates the optimal action-
value function [14]. During a temporal-difference learning process, previous predictions are used 
as a targets for next predictions in order to solve the prediction problem [36]. Furthermore, most 
of those algorithms found in the literature are on-policy methods that evaluate the same policy 
that is used to make decisions. Otherwise, off-policy methods evaluate a policy which is different 
than the policy used to obtain the data. Moreover, although in most of the literature learning 
method information is not included, we found more cases based on on-line learning, in which 
learning is performed as the data is coming in, than on off-line learning where there is a static 
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dataset. It is worth mentioning articles in which a policy is learning off-line in a first stage using 
stored data, and then this policy is adapted on-line for the patient [16, 29, 33]. Finally, most of the 
articles in the literature use the IHD model to decide how the future is considered in the actions 
made by the agent about how to behave in the current time step. These are typical situations in 
mHealth applications, in which we usually have an on-line estimation of optimal treatment 
strategies as data continuously accumulate, as well as no definite time horizon taking into account 
the long-run reward of the agent [37]. This scenario is reflected in the BG control task, where a 
CGM yields a continuous flux of BG measurements. 
Further comparison between different RL algorithms is performed in [36], were policy gradient 
and tabular methods are compared. In this paper, AC algorithm shows better performance than 
sarsa. This is because sarsa starts completely from scratch, while AC starts from a reasonable 
policy from which knows its structure. Furthermore, we are trying to face a continuous action 
task and sarsa is designed for discrete action space, while AC is designed for continuous action 
space [36]. This paper also compares traditional supervised learning with RL methods. In this 
regard, RL does not require any knowledge on the parameters of the policy, but supervised 
learning needs this information. Moreover, supervised learning needs shorter training period 
than RL because of the generalization ability of the former. However, RL algorithms continuously 
learn from new data, while supervised learning does not adjust to the patient after the training 
period, loosing this extra information. Therefore, glucose pattern in diabetes keeps changing and 
RL methods can adapt to this change, but supervised learning algorithms cannot [53]. 
Proportional-integral-derivative control algorithm and self-managed control by the patient are 
compared with RL methods in [45]. From this study, RL algorithms were able to outperform 
traditional approaches under certain circumstances, although they do not outperform the 
proportional-integral-derivative controller across all settings [45]. This kind of control algorithms 
are considered one of the most used techniques in the AP framework [54]. Moreover, the impact 
of errors in CHO estimation is analyzed in [49]. This paper tests the performance of proportional-
integral-derivative controller, bolus calculator [55] and RL algorithm under different CHO 
estimation error levels. In this work, RL algorithm outperforms traditional approaches, achieving 
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stable blood glucose control performance under all different conditions. Furthermore, categorical 
CHO announcement using three different levels (small, medium, and large) has low or no impact 
on the blood glucose control when errors in CHO estimation are lower than ±25%, indicating that 
the algorithms do not need accurate meal announcements [49]. 
The trade-off between exploration and exploitation is one of the unique characteristics that 
differentiate the RL algorithms from others ML approaches. Therefore, how to perform it is one 
of the choices we must make when we are going to implement a RL algorithm. However, we 
extracted from the results that in many cases this issue is not defined. This is because in most of 
that cases AC algorithms and therefore policy gradient methods are used, and for these 
algorithms we only generally require that the policy never becomes deterministic in order to 
ensure the exploration [14]. Therefore, in practice it is enough to choose a stochastic policy to 
solve the exploration-exploitation dilemma, and in some of these studies those policies are not 
specified. Moreover, we found that Gaussian distribution functions are very frequently used to 
deal with this issue. It is worth mentioning the use of 𝜀𝜀-greedy exploration, since it is a really 
simple method in which instead of taking in each state always the action with greatest value, we 
choose from time to time a random action with small probability 𝜀𝜀 in order to ensure the 
exploration. 
Another of the most important choices we must take during RL algorithm implementation is the 
definition of the state and action spaces. First of all, we found that most of these spaces are defined 
as continuous. As we mentioned above, this is because of the nature of the problem, in which we 
expected to have continuous BG measurements and continuous insulin infusion rate. 
Accordingly, in the BG control problem we will always have at least two information sources: BG 
level and insulin doses. Therefore, it is natural in the RL framework to relate that information 
with the states and actions respectively. There are various definitions of the state space in the 
reviewed literatures, all of them somehow related to the BG level. Concretely, most of the authors 
define the state space based only on the BG level, followed by these studies in which the states 
take into account not only the BG level, but also the insulin doses. Regarding the action space, 
there is only one study in which the actions are not based on the insulin doses [41]. In this paper, 
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the authors take the actions choosing the best glycemic target under different circumstances, 
leaving the choice of agents and doses to achieve that target to the clinicians. It is worth to mention 
two articles in which not only the quantity of insulin is used as an action, but also the kind of 
insulin used [22], such us short-acting, intermediate-acting or long-acting, and even a 
combination of those different insulins [35]. However, several additional factors affect the BG 
level such us CHO intake, PA, stress level, infections, etc [56]. This means that the use of this 
information is useful in order to face the BG control problem, so we expected to find this data as 
part of the state and action spaces. However, there are few papers in which for example CHO 
intakes and PA are included in the state space, although this information is really relevant for the 
algorithm and facilitates its operation. Furthermore, there is a lack of automatic CHO recording 
since in those cases this task relies on manual recording. In order to reduce the burden on the 
patient, as well as increase the objectivity during the control task, the combination of RL 
algorithms with meal detection algorithms such as [57, 58] could be part of future perspectives in 
order to work in a fully closed-loop system. Concerning the action space, we found that despite 
the importance of the PA and CHO intakes, there is only one paper in the literature in which this 
value information is indeed taking into account as part of the actions [37]. This action space is 
formed by a hypothetical mHealth intervention where insulin injections are administered using 
an insulin pump while suggestions for food intake and PA are administered using a mobile app, 
considering all possible combinations of insulin injection, food intake, and PA. 
The model of the environment is another element of model-based RL systems. The models are 
used for planning or predicting the next state and the next reward. In this stage we have to decide 
if we want to use a model-based method or a model-free method in which the learner behavior is 
based on trial and error. What we found here is that most of the authors based their algorithms 
on model-free methods. It can be explained by the fact that it is difficult to obtain realistic 
metabolic models for a real person. Furthermore, it is expected that RL algorithms becomes a 
personalized solution learning from the real patient, and each person presents different 




Finally, the choice of a good reward function is crucial for the correct performance of the 
algorithm. This is the way we have to communicate to the agent what we want to achieve, thereby 
defining the goal in the RL problem [14]. Therefore, in our BG control problem, the reward 
function should reflect our desire to stay inside the normal glycemic range. In general, these may 
be stochastic functions of the state of the environment and the actions taken. Since the reward 
function is freely defined by the authors, in this category we found very varied reward functions 
as we can see in Table 15. In general terms, we found that most of reward functions are related 
with the BG level in some way and consequently with the state of the environment. There is only 
one case that does not take into account the BG level [41]. This is because the study is focused on 
severely ill septic patients and in this situation the survival of patients is the main objective of 
clinicians for critical care. It is also common to find some reference values related to normal, hyper 
and hypoglycemia ranges in order to establish good rewards and penalties. However, we found 
that only five papers include the actions taken in the reward function [31, 32, 38, 42, 44]. We think 
it could be interesting to also consider the insulin doses in the reward function, which for example 
can lead to take less aggressive actions for the patients. The success of a RL application strongly 
depends on how well the reward function frames the goal of the application's designer and how 
well the function assesses progress in reaching that goal [14]. 
In order to measure the performance of these algorithms, the authors usually predefine target 
ranges since in the BG control problem we aim to spend as much time as possible in normal 
glycemia, which is between 70 and 130 mg/dL with a mean normal value of 100 mg/dL. This 
means that in this task it is quite easy to establish desired ranges and reference values. Another 
quite common technique to evaluate the efficacy of the glucose regulation algorithms is the 
CVGA, which shows the glucose excursions caused by a control algorithm in a group of patients, 
providing a summary of the quality of glycemic regulation for a population of subjects [60]. This 
method is complementary to the low blood glucose indices (LBGI) measurement, which 





Recent research in diabetes area has produced new advances and technologies such as sensors, 
new insulins, monitoring devices, etc. On the one hand these discoveries facilitate the adoption 
of new techniques such as ML methods and the idea of the AP, but on the other hand the problem 
becomes more complex. At this point, RL algorithms emerge as a smart, personalized and optimal 
solution to calculate insulin delivery. In this regard, it is worth to mention this recent patent 
related to estimate insulin dose based on RL [62], and this patent that uses RL combined with 
neural network to optimize patient treatment recommendations [63], in which diabetes is used as 
a practical example of application. However, RL is still a recent approach in the diabetes area and 
there are few papers which explicitly use this class of algorithms in the BG control problem. For 
such purpose, we expected to find a model-free RL algorithm based on an approximate solution 
method, using continuous state an action spaces, learning on-line and following the IHD model, 
some of them being typical characteristics of mHealth systems. This is because of the nature of 
the problem, in which we continuously expect to receive BG measurements from a CGM 
indefinitely and learning according to the data is obtained, while at the end stage we are not able 
to know the model of the patient. Those expected features perfectly match with the trends we 
found in the literature during this systematic review. 
Moreover, despite several factors, such as CHO intakes, PA, infections, or stress level, influence 
the BG, there are few papers in the reviewed literature which include these factors in the state 
and action spaces. This is, in particular, the case if we talk about the action space where there is 
only one study that considers PA and food intakes as part of the possible actions [37]. Therefore, 
we consider inclusion of some of these factors in the BG control problem to be a very important 
future research direction. For example, it would be possible to use meal detection [57, 58] or CHO 
counting algorithms [64] to include the food intake information as a part of the state and action 
spaces. Another option could be a sensor mounted on a tooth transmitting information on glucose 
intake [65]. Moreover, nowadays the use of mobile devices and other wearables is quite common, 
therefore the inclusion of the PA in the state and action spaces would be really easy. This would 
allow the creation of a mHealth system for self-management diabetes controlled by a mobile app 
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[66], in which BG level, insulin doses, food intake and PA are combined to deal with the BG 
control problem. However, although the inclusion of that additional information would be easy, 
the difficulties come with how such information can be correctly used by the RL algorithm, which 
in our opinion is the next challenge developers have to overcome to obtain a fully closed-loop AP 
system. In addition to the integration of additional systems for the estimation of the accurate CHO 
intake during meals as well as PA, an early warning system in order to forecast and predict 
hyper/hypoglycemic events would be extremely valuable [67]. 
Furthermore, to perform evaluation experiments on diabetic patients may be neither possible, 
appropriate, convenient nor desirable, since some of these experiments cannot be done at all or 
are too difficult, dangerous and not ethical [68]. Moreover, different countries have different 
execution procedures and regulatory conditions. For this reason, simulators are really necessary 
in order to deal with the diabetes framework, because these allow us to design, evaluate and 
verify the effectiveness of the BG controller before clinical tests. This is particularly important in 
the case of RL, where a continuous interaction with the patient is needed in order to learn the 
correct amount of insulin for each situation. However, there exist few papers in the literature 
using real data, therefore it is necessary to obtain and use more clinical data in order to clinically 
validate the algorithms. 
Finally, traditional RL algorithms requires carefully chosen feature representations. Therefore, it 
would be interesting to test other RL approaches such us deep reinforcement learning [45], in 
which deep learning is used for learning feature representations, that in the traditional 
framework are usually hand-engineered [69]. Another possibility would be to combine 
supervised learning with RL, since the latter requires an extensive amount of training data in 
order to converge to a meaningful solution, restricting its usage for complex input spaces [70]. In 
such scenarios, it would be possible to learn from the past historical records of the subject BG 
level before start to learn directly from the patient, accelerating convergence and reducing the 
amount of time needed by the controller to stay in normoglycemic range, thereby facilitating 
clinical trials. Other approaches have been used in the literature for that purpose, for example 
[21, 30, 34, 47] and [49] use transfer entropy to automatically initialize the control algorithm in a 
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personalized fashion, providing faster learning rate. This method is a measurement of the 
information transfer between insulin and glucose signals, with promising application in 
biomedical signal analysis [71]. 
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